Fresh analysis indicates that people who stop using popular slimming jabs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who halt conventional diet and exercise programs.
Published data in a major medical journal demonstrates that while overweight people often shed about a fifth of their body weight while using the jabs, the weight returns at an average rate of 0.8 kg per month once they quit.
"Users buying such drugs need to be aware of the risk of quick rebound weight gain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
Such speed of regain suggests a reversion to original mass within about 18 months.
Weighing Approaches
The research, which looked at dozens of studies involving over 9,000 of participants, contrasted the effects of these new drugs with other pills.
Researchers emphasize that people who lose weight through diet and exercise usually experience a more gradual weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Rapid Rebound
Experts suggest the mode of action of the drugs accounts for the accelerated rebound.
The injections imitate a body's own chemical called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels far above than normal might result in the body to produce less of its own natural hormone, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' leads to hunger is unsuppressed, making excessive eating a significant risk."
An Ongoing Condition?
Health authorities advise the injections for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Professionals argue that, considering the high risk of weight regain, the therapy might need to be ongoing.
This opinion is reinforced by drug manufacturers, who say that the results "underscore the long-term character of excess weight," akin to managing conditions like hypertension.
Patient Testimonies
Individuals who have come off the medication describe a powerful resurgence of hunger.
"I experienced a switch activating and I was suddenly ravenous," recalled a patient.
The struggle is worsened if users have not developed sustainable lifestyle or habit changes during treatment.
Significant Use
Figures show that millions of adults in the UK have used these injections in the past year, with demand remaining high.
- Use is greater among females than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a magic solution and lasting health benefits relies on ongoing behavioural management.
